Not only were baseline TNFR levels associated with the progression of kidney disease, but also a smaller difference in TNFR levels between baseline and 1 year after SGLT2 inhibitor treatment was associated with better subsequent kidney outcomes22,23. This evidence concerns the gene TNFRSF1A and kidney disorder.